Estimation of the contribution of norketamine to ketamine-induced acute pain relief and neurocognitive impairment in healthy volunteers

Anesthesiology

Volumn 117, Issue 2, 2012, Pages 353-364

  Olofsen, Erik ^a   Noppers, Ingeborg ^a   Niesters, Marieke ^a   Kharasch, Evan ^b   Aarts, Leon ^a   Sarton, Elise ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; KETAMINE; NORKETAMINE; PLACEBO; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; BEDTIME DOSAGE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ACUTE PAIN; ADOLESCENT; ADULT; ANALGESICS; COGNITION; HOT TEMPERATURE; HUMANS; KETAMINE; MALE; MEMORY; PAIN MANAGEMENT; PAIN MEASUREMENT; PSYCHOMOTOR PERFORMANCE; REACTION TIME; REFERENCE VALUES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84864284434     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31825b6c91     Document Type: Article

References (30)

1. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73:107-21.
2. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: Absence of sex differences. Anesthesiology 2004; 100: 120-33.
3. Petrenko AB, Yamakura T, Baba H, Shimoji K: The role of N-methyl-D-aspartate (NMDA) receptors in pain: A review. Anesth Analg 2003; 97:1108-16.
4. Bell R, Eccleston C, Kalso E: Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003: CD003351.
5. Nesher N, Serovian I, Marouani N, Chazan S, Weinbroum AA: Ketamine spares morphine consumption after transthoracic lung and heart surgery without adverse hemodynamic effects. Pharmacol Res 2008; 58:38-44.
6. Sigtermans M, Dahan A, Mooren R, Bauer M, Kest B, Sarton E, Olofsen E: S()-ketamine effect on experimental pain and cardiac output: A population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009; 111:892-903.
7. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM: Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333:99-104.
8. Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP: Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008; 90:676-85.
9. Leung LY, Baillie TA: Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 29:2396-9.
10. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE: Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine. Pain 1999; 81:85-93.
11. Noppers I, Olofsen E, Niesters M, Aarts L, Mooren R, Dahan A, Kharasch E, Sarton E: Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology 2011; 114:1435-45.
12. Swartjes M, Morariu A, Niesters M, Aarts L, Dahan A: Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. Anesthesiology 2011; 115:165-74.
13. Olofsen E, Romberg R, Bijl H, Mooren R, Engbers F, Kest B, Dahan A: Alfentanil and placebo analgesia: No sex differences detected in models of experimental pain. Anesthesiology 2005; 103:130-9.
14. Gualtieri CT, Johnson LG: Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 2006; 21:623-43.
15. Beal BL, Sheiner LB, Boeckman AJ, Bauer RJ: NONMEM User's Guide. Ellicott City, Maryland, ICON Development Solutions, pp. 1989-2009.
16. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A: Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010; 11:2417-29.
17. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC: Psychological effects of ketamine in healthy volunteers: Phenomenological study. Br J Psychiatry 2006; 189:173-9.
18. Passie T, Karst M, Wiese B, Emrich HM, Schneider U: Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology 2005; 51:226-33.
19. Mitchell AC: Generalized hyperalgesia and allodynia following abrupt cessation of subcutaneous ketamine infusion. Palliat Med 1999; 13:427-8.
20. Niesters M, Dahan A, Swartjes M, Noppers I, Fillingim RB, Aarts L, Sarton EY: Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011; 152:656-63.
21. Sigtermans M, Noppers I, Sarton E, Bauer M, Mooren R, Olofsen E, Dahan A: An observational study on the effect of S-ketamine on chronic versus experimental acute pain in complex regional pain syndrome type 1 patients. Eur J Pain 2010; 14:302-7.
22. Schmidt AP, Tort AB, Silveira PP, Böhmer AE, Hansel G, Knorr L, Schallenberger C, Dalmaz C, Elisabetsky E, Crestana RH, Lara DR, Souza DO: The NMDA antagonist MK-801 induces hyperalgesia and increases CSF excitatory amino acids in rats: Reversal by guanosine. Pharmacol Biochem Behav 2009; 91:549-53.
23. Guan Y, Terayama R, Dubner R, Ren K: Plasticity in excitatory amino acid receptor-mediated descending pain modulation after inflammation. J Pharmacol Exp Ther 2002; 300: 513-20.
24. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995; 77:355-9.
25. Maurice T, Su TP: The pharmacology of sigma-1 receptors. Pharmacol Ther 2009; 124:195-206.
26. Schüttler J, Stanski DR, White PF, Trevor AJ, Horai Y, Verotta D, Sheiner LB: Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. J Pharmacokinet Biopharm 1987; 15:241-53.
27. Herd DW, Anderson BJ, Keene NA, Holford NH: Investigating the pharmacodynamics of ketamine in children. Paediatr Anaesth 2008; 18:36-42.
28. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A: Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 2003; 99:788-98.
29. Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, Sarton E: Naloxone reversal of morphine-and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: A mechanism-based pharmacokineticpharmacodynamic modeling study. Anesthesiology 2010; 112:1417-27.
30. Olofsen E, Mooren R, van Dorp E, Aarts L, Smith T, den Hartigh J, Dahan A, Sarton E: Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates Anesth Analg 2010; 111:626-32